Well, we finally got the news. I expect MDWD to grind higher now that it is confirmed and phase 3 is starting (remember one person who used to routinely post on this board it was a short said it would never get off the ground). Parameters for the study are also better than expected. Just a matter of time now. Long road ahead, but given outcome in Europe for their studies there, it's a given, just a few years down the road (if it isn't ended sooner for favorable results). Buy on the big pullbacks to 5s and 6s from here on out.
search for the clinicaltrials dot gov site for MDWD study. I'd link you but yahoo hates links. Just google what I put there or something close.
It had been dormant forever, but just in the last month or two they started changing lots of things. You can track the history of changes on the site. The key takeaway from the changes is the company has obviously met with the folks about the trial and have updated it quite in depth about the study. So things are getting very close.
The company unfortunately is taking a hard line and won't announce the phase 3 is actually under way until they have started it with the first patient. At least that's what IR has stated. So things are certainly in motion, and they require recruitment etc first, but things are finally happening.
Definitely a spec though. EscharEx data should be coming as well by end of the year. And the pediatric study for Nexobrid is ongoing in Europe (who are much more forgiving than the FDA).
It is GOOD news. Let's just say that long elusive phase 3 trial in the USA is finally starting to get traction after a long long time of hearing nothing. It's taking shape, and will be signed off on and start enrolling soon. It's public info if you know where to look, which any biotech investor should know where to find it.